Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.
Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. Rosenbaum JT, et al. Among authors: zierhut m. Semin Arthritis Rheum. 2019 Dec;49(3):438-445. doi: 10.1016/j.semarthrit.2019.06.004. Epub 2019 Jun 10. Semin Arthritis Rheum. 2019. PMID: 31301816 Free article. Review.
Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic.
Agrawal R, Testi I, Lee CS, Tsui E, Blazes M, Thorne JE, Okada AA, Smith JR, McCluskey PJ, Kempen JH, Tappeiner C, Agarwal M, Bodaghi B, Nguyen QD, Gupta V, De Smet MD, Zierhut M, Pavesio C; COVID-19 IMT Study Group. Agrawal R, et al. Among authors: zierhut m. Br J Ophthalmol. 2021 May;105(5):639-647. doi: 10.1136/bjophthalmol-2020-316776. Epub 2020 Jun 25. Br J Ophthalmol. 2021. PMID: 32586933 Free PMC article.
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT. Suhler EB, et al. Among authors: zierhut m. Ophthalmology. 2021 Jun;128(6):899-909. doi: 10.1016/j.ophtha.2020.10.036. Epub 2020 Nov 3. Ophthalmology. 2021. PMID: 33157077 Free article. Clinical Trial.
Genetics of Uveitis.
Cunningham ET Jr, Pichi F, Mahajan VB, Rosenbaum JT, Zierhut M. Cunningham ET Jr, et al. Among authors: zierhut m. Ocul Immunol Inflamm. 2021 Feb 17;29(2):215-218. doi: 10.1080/09273948.2021.1910430. Ocul Immunol Inflamm. 2021. PMID: 33950774 No abstract available.
Therapy of ocular Behçet disease.
Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Zierhut M, et al. Ocul Immunol Inflamm. 2014 Feb;22(1):64-76. doi: 10.3109/09273948.2013.866257. Epub 2013 Dec 30. Ocul Immunol Inflamm. 2014. PMID: 24377434 Review.
Behçet Uveitis.
Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M. Cunningham ET Jr, et al. Among authors: zierhut m. Ocul Immunol Inflamm. 2017 Feb;25(1):2-6. doi: 10.1080/09273948.2017.1279840. Ocul Immunol Inflamm. 2017. PMID: 28195819 No abstract available.
Multiple Sclerosis-Associated Uveitis.
Cunningham ET Jr, Pavesio CE, Goldstein DA, Forooghian F, Zierhut M. Cunningham ET Jr, et al. Among authors: zierhut m. Ocul Immunol Inflamm. 2017 Jun;25(3):299-301. doi: 10.1080/09273948.2017.1334469. Ocul Immunol Inflamm. 2017. PMID: 28696171 No abstract available.
Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD. Suhler EB, et al. Among authors: zierhut m. Ophthalmology. 2018 Jul;125(7):1075-1087. doi: 10.1016/j.ophtha.2017.12.039. Epub 2018 Feb 9. Ophthalmology. 2018. PMID: 29429764 Free article. Clinical Trial.
Medical Therapy of Uveitic Macular Edema: Biologic Agents.
Radosavljevic A, Agarwal M, Bodaghi B, Smith JR, Zierhut M. Radosavljevic A, et al. Among authors: zierhut m. Ocul Immunol Inflamm. 2020 Nov 16;28(8):1239-1250. doi: 10.1080/09273948.2019.1709648. Epub 2020 Feb 14. Ocul Immunol Inflamm. 2020. PMID: 32058830 Review.
340 results